Glycomine initiates Phase 2 trial of GLM101 for PMM2-CDG
Glycomine, Inc. is conducting Phase 2 trial to evaluate GLM101 in PMM2-CDG patients, comparing it to placebo over 48 weeks.
Asset / Drug
Drug and asset intelligence for GLM101 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.